Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
about
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Promising oncolytic agents for metastatic breast cancer treatmentTrial Watch:: Oncolytic viruses for cancer therapyExperimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Targeting tumor vasculature through oncolytic virotherapy: recent advances.Evolution of oncolytic viruses: novel strategies for cancer treatment.Translational regulator eIF2α in tumor.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Fighting Cancer with Mathematics and Viruses.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.VSV based virotherapy in ovarian cancer: the past, the present and …future?Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Review: Oncolytic virotherapy, updates and future directions.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Tumor Restrictions to Oncolytic Virus.RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS.
P2860
Q26775030-DAFBF3B9-25E3-4CD7-BF62-8B541DDE86F2Q26830620-5D48CC3C-4FDF-458C-B3F8-6578D1EA830BQ27021951-FD0A9DD7-9337-4ABB-9219-6B41295F5DD3Q33882758-C62DEDA9-30E5-4EC0-8613-03F58D57C7DDQ36751597-D8315D50-B50E-4591-AB61-9FF9886F3511Q37031932-EBEF524B-F71A-47AE-813B-6AED334A0D74Q38159802-F119EF24-DDBA-4112-8B4C-1D19E421E017Q38194482-552CDCAD-5759-4B0D-A52F-5CB1683D5C59Q38223419-9C81D46E-2AFD-4A43-BFD2-D62765B97E61Q38237657-6C96C89E-4572-432E-A12A-F43C7F75ACE1Q38612646-0860F221-A0ED-4BFE-8A44-653EABF72054Q39387174-D8B5BD36-3D05-47C3-8317-4AE24F295F9BQ41441101-C8C59850-78AD-4DA6-B452-37942F45998BQ41932925-5B96201D-9BBC-4FED-9AAC-B2F9AC4AB94DQ45324769-47D15D54-4CE4-4140-B4A5-6A03284AE4F9Q47160989-6DC53772-5C9D-42E7-B9FC-16EB7FC1107AQ50056861-E0B3ED44-2F07-4B14-8213-106DD8F0C809Q51846287-9AABD59B-F2CC-4900-A3B8-036FA40F4DA3Q55456991-E73DDA37-83C0-435D-A4D7-1B1765D73CAA
P2860
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
@en
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
@nl
type
label
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
@en
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
@nl
prefLabel
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
@en
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy
@en
P2093
Beihua Dong
Carvell T Nguyen
Irina Polyakova
P2860
P304
P356
10.1038/MT.2013.112
P577
2013-06-04T00:00:00Z